[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Rochester\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,110,0,25,[9,36,63,94,117,142,169,195,220,244,268,289,310,338,359,378,401,422,443,467,493,520,545,567,594],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100634036","echocardiographic-assessment-of-the-effect-of-impella-on-biventricular-function-100634036",false,"NCT07534462","Echocardiographic Assessment of the Effect of Impella on Biventricular Function","Inclusion Criteria:\n\n1. Adult patients over 18 years old\n2. Require Impella 5.5 implantation\n\nExclusion Criteria:\n\n1. Patients' inability to provide consent for themselves (including that patients' lack of understanding the research)\n2. Any patients who are deemed at higher-than-normal risk for complications secondary to echocardiography, such as dysphagia or esophageal pathology","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","OBSERVATIONAL","The objective of this prospective observational study is to evaluate the effects of Impella 5.5 on biventricular function in adult patients with end-stage heart failure requiring temporary mechanical circulatory support. The study will assess changes in left and right ventricular global longitudinal strain and myocardial work, as well as additional echocardiographic and hemodynamic parameters. Measurements will be obtained at baseline prior to Impella implantation, immediately after device initiation, and during postoperative follow-up up to Day 14. This study involves collection of echocardiographic imaging and clinical data, including additional imaging performed for research purposes.",[24],"End-stage Heart Failure","NOT_YET_RECRUITING","2026-06-27",{"date":28,"type":29},"2026-07-01","ACTUAL",{"date":28,"type":20},{"date":32,"type":20},"2027-07-01",{"name":34,"class":35},"University of Rochester","OTHER",{"id":37,"slug":38,"hasResults":12,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100595452","reducing-crises-and-suicide-within-the-idaho-army-national-guard-100595452","NCT07032636","Reducing Crises and Suicide Within the Idaho Army National Guard","Reducing Crises and Suicide Within the Idaho Army National Guard - Enhancement of the First Line Leader Program","Inclusion Criteria:\n\n* Enlistment or commission in the Idaho ARNG at the time of enrollment\n* Age 18 or greater\n* Ability to complete all study questionnaires and interview procedures\n* Has at least one year remaining on National Guard contract\n\nExclusion Criteria:\n\n\\- Less than one year remaining on their contract with the National Guard",true,{"count":45,"type":20},450,"INTERVENTIONAL",[48],"NA","Military suicide is an ongoing public health concern, particularly within the Army National Guard (ARNG), with longstanding effects on fellow soldiers, family, and friends. The straddling of military and civilian worlds for ARNG can worsen risk factors for suicide, including increased social isolation, disruption to family life, and employment difficulties. One promising framework that addresses both unit cohesion and social support is the First Line Leaders (FLL) program, recently designated by ARNG for nation-wide dissemination. The program is centered on enhancing the relationship between junior enlisted soldiers (JES) and their assigned non-commissioned officer (NCO). The Investigators propose to study an augmented FLL program that includes templated guides developed in collaboration with Idaho ARNG stakeholders. The guides, referred to as TAP (Total Health Action Plan), were adapted from two empirically based interventions, Crisis Response Planning and Problem-Solving Therapy, and consist of prompts for open communication and effective engagement and guidelines for responding to impending or current behavioral distress. Given their elevated suicide risk, the Idaho ARNG is a crucial setting to develop this upstream intervention.\n\nIn this study, the Investigators propose to compare the augmented FLL + TAP program to FLL only, and training as usual (n= 50 NCOs and 100 JES per group) with quarterly assessments for up to one year. The Investigators will examine a random selection of deidentified counseling templates to examine the type and frequency of counseling sessions involving acute crisis and behavioral health difficulties, and online ratings from a random selection of JES using validated instruments to assess upstream indicators of behavioral distress and suicide risk and resilience. The Investigators will also conduct qualitative interviews with a random selection of 20% of the NCOs (n = 30) and JES (n = 60) enrolled in the project to provide personalized perspectives of program experiences.\n\nThe Investigators propose three aims to guide this research. (1) Collaborate with Idaho ARNG stakeholders to integrate TAP into FLL programming via: a) development and refinement of TAP training materials, b) building templated counseling statements that align with FLL and TAP, and c) education of Idaho ARNG training cadre in the delivery of TAP. (2) Evaluate fidelity, feasibility, and acceptability of FLL and FLL + TAP through a mixed methods approach of qualitative interviews with FLLs and JESs and evaluation of data from templated counseling sessions. (3) Examine the impact of FLL+TAP versus FLL versus training as usual on unit morale, cohesion, and general functioning.",[51,52],"Crisis Response Plan","Crisis Intervention","RECRUITING","2026-06-25",{"date":56,"type":29},"2026-06-26",{"date":58,"type":29},"2026-06-15",{"date":60,"type":20},"2028-05-01",{"name":34,"class":35},1,{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":46,"phases":71,"briefSummary":72,"conditions":73,"keywords":80,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":62},"100614420","deaf-cbt-ts-to-reduce-suicide-risk-100614420","NCT07279363","Deaf CBT-TS to Reduce Suicide Risk","Cognitive Behavioral Therapy for Treatment-Seeking to Improve Treatment Engagement and Reduce Suicide Risk Among Deaf Individuals","Inclusion criteria:\n\n* adult (aged 18 years or older)\n* Self-identify as Deaf or hard of hearing (any degree of hearing loss)\n* Primary method of communication is American Sign Language\n* Positive screen for one or more mental health disorders including depression (PHQ-9 \\> 10), anxiety (GAD-7 \\> 10), posttraumatic stress disorder (PCL-5 \\> 31), insomnia (ISI \\> 15), or alcohol use disorder (AUDIT \\> 16)\n* No current professional mental health or alcohol specialty treatment (e.g., counseling, psychiatric services) per standardized self-report\n* Access to video chat technology with internet and webcam.\n\nExclusion criteria:\n\n* unable to communicate with the researcher in American Sign Language\n* current alcohol withdrawal necessitating medical evaluation\n* current psychiatric impairment necessitating emergency services or inpatient admission (i.e., imminent danger of harm to self or others)\n* unable to comprehend the nature of the study",{"count":5,"type":20},[48],"The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are:\n\n* Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors?\n* Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use?\n* Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress?\n* Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors.\n\nParticipants will:\n\n* Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment.\n* Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months\n* Complete two follow-up assessments in 2 and 4 months.",[74,75,76,77,78,79],"Depression - Major Depressive Disorder","Anxiety","PTSD - Post Traumatic Stress Disorder","Insomnia","Alcohol Use Disorder (AUD)","Suicide Ideation",[81,82,83,84,85],"Deaf","Mental Health","Treatment-Seeking","Suicide","Cognitive Behavioral Therapy for Treatment-Seeking","2026-06-17",{"date":88,"type":29},"2026-06-22",{"date":90,"type":20},"2026-09",{"date":92,"type":20},"2029-05",{"name":34,"class":35},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":16,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":46,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100642672","prophylactic-pulmonary-vein-isolation-during-atrial-flutter-ablation-100642672","NCT07649603","Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation","Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation: The PREVENT-AF Study II","PREVENT-AF II","Inclusion Criteria:\n\n1. Age ≥ 55 years on date of consent\n2. History of typical AFL and plans for a guideline-supported catheter ablation for AFL - including paroxysmal AFL defined as AFL with duration of up to 7 days and persistent AFL as longer than 7 days or if interrupted by cardioversion for clinical reasons and up to 1 year\n3. Left atrial diameter ≥ 4.5 cm within 12 calendar months prior to or on consent date by transthoracic echocardiography\n4. No identifiable AF on any prior ECG within past 1 year\n5. CHA2DS2 -VASc ≥ 2\n\nExclusion Criteria:\n\n1. Inability to undergo or AFL or AF catheter ablation (e.g., presence of a left atrial thrombus)\n2. AFL or AF due to reversible cause e.g. hyperthyroid state\n3. Contraindication to systemic anticoagulation\n4. Prior surgical or percutaneous cardiac ablation procedure any time in the past\n5. Prior AFL ablation (e.g. CTI) or PVI ablation any time in the past\n6. LV ejection fraction \\\u003C 35%\n7. Paroxysmal, persistent or longstanding persistent AF\n8. Presence of NYHA Class IV congestive heart failure\n9. Acute coronary syndrome or coronary artery bypass surgery or percutaneous coronary intervention (balloon and\u002For stent angioplasty) within 3 calendar months prior to consent date\n10. Enzyme-positive myocardial infarction within the past 3 calendar months prior to consent\n11. Severe aortic or mitral valvular heart disease eligible for percutaneous or surgical repair\u002Freplacement procedures\n12. Angiographic evidence of coronary disease that requires coronary revascularization and with likelihood of undergoing a CABG or PCI in the next 3 calendar months following consent date\n13. Any medical condition likely to limit survival to \\\u003C 1 year\n14. Renal failure requiring dialysis at time of consent\n15. Pregnancy\n16. History of non-compliance to medical therapy\n17. Participation in other clinical trials (observational\u002Flead registries are allowed) without approval from the DCC\n18. Inability or unwillingness to provide informed consent\n19. Resides at such a distance from the enrolling site so travel to follow-up visits would be unusually difficult\n20. Does not anticipate residing in the vicinity of the enrolling site for the duration of the trial","55 Years",{"count":104,"type":20},620,[48],"Pulmonary vein isolation (PVI) via catheter ablation has been successfully employed for years to treat symptomatic atrial fibrillation (AF). Moreover, PVI has not been used as a prophylactic intervention even in groups known to be high-risk for the future development of AF. Preliminary studies, including our pilot PREVENT AF I randomized trial, suggested that prophylactic PVI may be effective at reducing new onset AF and overall AF burden in atrial flutter (AFL) patients.\n\nThis is a multicenter single-blind randomized controlled trial, \"Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation\" (PREVENT AF II) to determine if PVI in conjunction with AFL ablation for patients with typical AFL results in a significant reduction in cardiac events and healthcare utilization.",[108],"Atrial Flutter Typical","2026-06-09",{"date":111,"type":29},"2026-06-16",{"date":113,"type":20},"2027-06",{"date":115,"type":20},"2032-05",{"name":34,"class":35},{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":16,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":62},"100621770","medical-cannabis-observational-study-for-antiemetic-intervention-in-chemotherapy-100621770","NCT07374939","Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy","MOSAIC","Inclusion Criteria:\n\n* Have a diagnosis of cancer with no previous chemotherapy treatments (aside from current treatment)\n* Be scheduled to receive treatment with a chemotherapeutic agent that is classified by the National Comprehensive Cancer Network (NCCN) as having a high emetogenic potential (\\>90% incidence) or moderate emetogenic potential (30-90% incidence).\n* Must be scheduled for a minimum of 3 additional chemotherapy cycles at the time of enrollment.\n* Chemotherapy agents may be given intravenously or orally.\n* Chemotherapy cycles must be at least two weeks apart.\n* For the purposes of this study, Day 1 is defined as the day of chemotherapy administration.\n* Chemotherapy may be for adjuvant, neoadjuvant, curative, or palliative intent.\n* Highly emetogenic - common types of chemotherapy\n\n  * AC combination defined as any chemotherapy regimen that contains an anthracycline and cyclophosphamide\n  * Carboplatin AUC ≥4\n  * Carmustine \\>250 mg\u002Fm2\n  * Cisplatin\n  * Cyclophosphamide \\>1,500 mg\u002Fm2\n  * Dacarbazine\n  * Doxorubicin ≥60 mg\u002Fm2\n  * Epirubicin \\>90 mg\u002Fm2\n  * Ifosfamide ≥2 g\u002Fm2 per dose\n  * Mechlorethamine\n  * Streptozocin\n* Moderately emetogenic - common types of chemotherapy:\n\n  * Aldesleukin \\>12-15 million IU\u002Fm2\n  * Amifostine \\>300 mg\u002Fm2\n  * Arsenic trioxide\n  * Azacitidine\n  * Bendamustine\n  * Busulfan\n  * Carboplatin AUC \\\u003C4\n  * Carmustined ≤250 mg\u002Fm2\n  * Clofarabine\n  * Cyclophosphamide ≤1500 mg\u002Fm2\n  * Cytarabine \\>200 mg\u002Fm2\n  * Dactinomycin\n  * Daunorubicin\n  * Dual-drug liposomal encapsulation of cytarabine and daunorubicin\n  * Dinutuximab\n  * Doxorubicind \\\u003C60 mg\u002Fm2\n  * Epirubicind ≤90 mg\u002Fm2\n  * Idarubicin\n  * Ifosfamided \\\u003C2 g\u002Fm2 per dose\n  * Interferon alfa ≥10 million IU\u002Fm2\n  * Irinotecan\n  * Irinotecan (liposomal)\n  * Melphalan\n  * Methotrexated ≥250 mg\u002Fm2\n  * Oxaliplatin\n  * Temozolomide\n  * Trabectedin\n* Be willing to commit to the suggested medication dosing and delivery method, completing evaluation instruments, and attending all study visits.\n* Be able to understand English (all assessment instruments are in English).\n* Be 21 years of age or older.\n* Give informed consent.\n* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, or abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.\n\nExclusion Criteria:\n\n* Participants must not:\n* Use of any THC-containing cannabis products within 30 days prior to enrollment, verified by participant self-report.\n\nAllowable: Use of hemp-derived CBD products containing \\\u003C 0.3 % THC is permitted, consistent with the 2018 Agriculture Improvement Act (federal definition of hemp). Use of CBD products will be documented in baseline case report forms.\n\n* Have any allergies to cannabis or contraindication for cannabis.\n* Have an active or recent (\\\u003C 6 months) substance use disorder, as determined by medical history.\n* Have recently quit smoking (\\\u003C 6 months) or are actively engaged in a smoking-cessation program.\n* Have a history of severe anxiety or paranoia on prior exposure to cannabis.\n* Have a previous diagnosis of bipolar disorder or schizophrenia.\n* Be pregnant or nursing.\n* Have had a prior stroke.\n* Have moderate or severe chronic obstructive pulmonary disease (COPD), defined as FEV₁ \\\u003C 50 % predicted or current use of home supplemental oxygen.","21 Years",{"count":126,"type":20},50,"The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients receiving chemotherapy that is known to cause nausea. The main questions it aims to answer are:\n\n* Is patient-directed medical cannabis use associated with reduced nausea severity during chemotherapy treatment?\n* Is-patient directed medical cannabis use associated with improved CINV control?\n* Is patient directed medical cannabis use associated with improved appetite during chemotherapy treatment?\n* Is patient-medical cannabis use associated with reduced treatment-related side effects, such as fatigue, sleep disturbances, general pain, and peripheral neuropathic pain?\n\nResearchers will compare participants who report using medical cannabis with participants who do not report using medical cannabis to determine whether differences exist in nausea, CINV outcomes, and other treatment-related symptoms.\n\nParticipants will be followed over the course of 3 chemotherapy cycles, and asked to complete questionnaires, nausea diaries, and partake in a blood sample collection. Study participation can last from 6 - 12 weeks, depending on their prescribed chemotherapy cycle frequency.",[129],"Nausea and Vomiting Chemotherapy-Induced",[131,132,133,134],"medical cannabis","chemotherapy-induced nausea and vomiting","nausea","nausea and vomiting","2026-06-04",{"date":109,"type":29},{"date":138,"type":20},"2026-09-01",{"date":140,"type":20},"2028-03-01",{"name":34,"class":35},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":46,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":62},"100613006","facilitating-lactation-through-optimized-workflows---evaluating-the-efficiency-of-pumping-protocols-and-cellular-mechanisms-of-milk-production-100613006","NCT07260968","Facilitating Lactation Through Optimized Workflows - Evaluating the Efficiency of Pumping Protocols and Cellular Mechanisms of Milk Production","FLOW","Inclusion Criteria:\n\n* English-speaking\n* Lactating parents of singleton, term infants less than 3 months of age\n* Intend to breastfeed and are breastfeeding (at the breast) at least 3 times per day\n\nExclusion criteria:\n\n* Twins and other multiples\n* Contraindications to or unable to breastfeed\n* Major congenital anomaly or unexpected surgery\n* Elevated maternal depression\n* Low milk transfer\n* No electricity or smartphone access","45 Years",{"count":151,"type":20},225,[48],"The purpose of this study is to evaluate the effectiveness of two different breast pumping protocols in increasing milk production among lactating individuals diagnosed with primary low milk supply, and to investigate the associated molecular, hormonal, and inflammatory mechanisms driving milk output.",[155],"Low Milk Supply",[157,158,159,160,161],"Lactation","Breastfeeding","Triple Feeding","Low milk production","Low milk supply","2026-06-02",{"date":135,"type":29},{"date":165,"type":29},"2026-05-07",{"date":167,"type":20},"2028-09-30",{"name":34,"class":35},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":16,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100588437","comparing-the-effectiveness-of-matched-related-donor-hematopoietic-stem-cell-transplantation-to-disease-modifying-therapy-in-pediatric-patients-with-sickle-cell-disease-100588437","NCT06941389","Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease","Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease.","WeDecide","Inclusion Criteria:\n\n* Pediatric patients aged between 3 and 20.9 years.\n* Children diagnosed with sickle cell Anemia (HB SS or HBSB0 Thalassemia)\n* For the MRD HCT group, children who are candidates for matched related donor hematopoietic stem cell transplantation (MRD HCT).\n* For the NT-DMT group, children who are receiving non-transplant disease-modifying therapies (NT-DMT) for SCD.\n* Participants (or their guardians) must provide informed consent to be part of the study.\n* Participants must be willing to undergo the necessary assessments and follow-up visits over the 3-year study period.\n\nExclusion Criteria:\n\n* Children younger than 3 years or older than 20.9 years.\n* Children who do not have sickle cell anemia or related conditions.\n* For the MRD HCT group, children who are not eligible for the transplant or do not have a matched related donor.\n* Children who are currently enrolled in other clinical trials that might interfere with the WeDecide study.\n* Children who are unable to adhere to the study protocol or follow-up requirements.","3 Years","20 Years",{"count":180,"type":20},480,"The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD HCT group and 320 in the NT-DMT group, aged 3-20.9 years, the study will follow participants for three years, examining factors like disease severity, treatment history, and social determinants of health. By providing a comprehensive comparison, the study seeks to inform clinical decisions and improve understanding of SCD treatment outcomes, ultimately supporting families and healthcare providers in choosing the best treatment options.",[183],"Sickle Cell Disease (SCD)",[185,186,187],"SCD","MRD HCT","NT DMT",{"date":135,"type":29},{"date":190,"type":29},"2024-06-01",{"date":192,"type":20},"2030-10-01",{"name":34,"class":35},37,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":46,"phases":204,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100385353","phase-1-study-of-pembrolizumab-and-single-agent-chemotherapy-as-first-line-treatment-for-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-eastern-cooperative-oncology-group-ecog-performance-status-of-2-100385353","NCT04297605","Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2","A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2","Inclusion Criteria:\n\n1. Participants must be \\>18 years old at time of diagnosis\n2. Histologically confirmed non-small cell lung cancer\n3. ECOG PS 2\n4. Clinical staging of IIIc or IV disease.\n\n4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation.\n\n4B. For patients with stage IV disease, platinum doublet chemotherapy is not appropriate, deemed unsafe by the treating physician, or declined by the patient\n\n4C. Screening lab work must meet the following parameters:\n\n4Ca. Absolute neutrophil count (ANC) ≥1000\u002Fmm3\n\n4Cb. Platelet count ≥100,000\u002Fmm3\n\n4Cc. CrCl\\>50 (if pemetrexed is to be offered)\n\n4Cd. AST and ALT ≤ 2.5 x ULN\n\n4D. Patients with small, asymptomatic brain metastases are eligible\n\n4E. Women of childbearing potential must be negative for pregnancy testing (urine or blood) and agree to use effective contraception. Viable contraception should be used after trial screening, before initiation of chemotherapy, and throughout the duration of active treatment in the study.\n\nNon-childbearing potential is defined as (by other than medical reasons): -Amenorrheic \\>2 years\n\n* Amenorrheic for \\\u003C2 years and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation\n* Post hysterectomy, oophorectomy or tubal ligation. Otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 120 days after the last dose of study drug\n\n  4F.Participants must read or be read and explained the purposes of the study and sign a statement of informed consent prior to participation. Those who do not read or understand English are eligible and may be consented according to institutional regulations.\n\nExclusion Criteria:\n\n1. Patients with history of autoimmune conditions with the following exceptions, which are allowed: alopecia, vitiligo, rheumatoid arthritis, psoriasis\u002Fpsoriatic arthritis, Hashimoto's thyroiditis\n2. Patients on immunosuppressive medication, including steroids (if doses exceed equivalent of prednisone 10 mg daily). Short courses of steroids which are discontinued prior to start of treatment are acceptable.\n3. Patients with cardiovascular, hepatic, or renal systemic diseases that would preclude use of chemotherapy and\u002For immunotherapy per the treating investigator.\n4. The patient must not be on any clinical trials involving other experimental therapies during study treatment\n5. Women who are currently pregnant or breast-feeding\n6. Patients with any other concurrent medical or psychiatric condition that were deemed inappropriate for entry into the study per the investigator.\n7. Symptomatic, untreated brain metastases. Patients with treated brain metastases may be considered eligible after completion of radiation if steroids have been tapered to less than equivalent of 10 mg of prednisone.\n8. Active infection requiring IV antibiotics",{"count":203,"type":20},60,[205],"PHASE1","The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.",[208],"Non-small Cell Lung Cancer",[210,208,211,212],"Eastern Cooperative Oncology Group (ECOG)","pembrolizumab","performance status of 2 (PS2)",{"date":135,"type":29},{"date":215,"type":29},"2020-05-15",{"date":217,"type":20},"2028-01-30",{"name":34,"class":35},2,{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":228,"minAge":17,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":46,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":62},"100637203","optimization-of-cardiac-imaging-in-women-with-early-stage-breast-cancer-100637203","NCT07630402","Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer","POCEB","Inclusion Criteria:\n\n* Female sex, age 18-79 years.\n* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT\n* Baseline LVEF ≥ 55 % by 2-D echocardiography.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Prior HF, myocardial infarction, or cardiomyopathy.\n* Atrial fibrillation or significant valvular heart disease.\n* Cumulative anthracycline dose ≥ 250 mg\u002Fm².\n* Pregnancy or lactation.\n* Inability to comply with study procedures.","FEMALE","79 Years",{"count":231,"type":20},20,[48],"The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).",[235],"Breast Cancer With Low to Intermediate HER2 Expression","2026-06-01",{"date":238,"type":29},"2026-06-05",{"date":240,"type":29},"2025-11-17",{"date":242,"type":20},"2031-06-30",{"name":34,"class":35},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":16,"minAge":252,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":62},"100640537","remote-assessments-and-genetic-determinants-of-congenital-and-childhood-myotonic-dystrophy-100640537","NCT07630389","Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy","REACH DM KIDS: Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy","REACH-DM KIDS","Inclusion Criteria:\n\n* Age 0-17 years\n* Clinical diagnosis of congenital, childhood, or juvenile DM1\n* English speaking\n* Parent or guardian willing to assist and provide consent for participation\n* If appropriate based on age and developmental level, child willing to provide assent for their own participation\n* Available wifi\n\nExclusion Criteria:\n\n* Presence of any other non-DM1 illness or disease (e.g. other neuromuscular disorder, cerebral palsy, or other genetic or acquired disorder affecting the central or peripheral nervous system) that could interfere with study results in the opinion of the site investigator\n* Significant recent trauma or injury prior to the RSV that could affect functional assessment","0 Years","17 Years",{"count":255,"type":20},100,"Myotonic dystrophy type 1 (DM1) can affect people in many different ways, even in the same family. The symptoms that children experience can be different and more severe than adults. Prior studies in children have been limited because only a small number of children could participate. In this study, we hope to learn more about these differences and what causes them.\n\nThis is an observational study conducted in participants' homes and does not require travel. Instead, we will use video calls to talk with children and their parents\u002Fguardians about DM1 symptoms and how it affects the child's muscles, heart, and brain. We'll send families an iPad and the other tools they need for the study. During the video call, kids will do some simple activities to see how their body moves and functions. Parents\u002Fguardians might need to help their child with some of these activities.\n\nAfter the video visit, we'll get a small blood sample from the child. This can be done at a local lab or even at home. We'll then look at the child's genes in the blood sample to understand how they might be linked to their symptoms. Parents\u002Fguardians can chose to have their child's genetic test result returned to them.",[258,259,260,261],"Myotonic Dystrophy Type 1","Congenital DM1","Juvenile DM1","Childhood DM1",{"date":238,"type":29},{"date":264,"type":29},"2023-11-13",{"date":266,"type":20},"2030-01-01",{"name":34,"class":35},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":62},"100558686","cardiopulmonary-exercise-testing-and-oscillometry-for-the-evaluation-of-dyspnea-100558686","NCT06554353","Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea","COED","Inclusion Criteria:\n\n* Willingness to perform breathing test\n* Must be able to speak and understand English\n* Referred for Cardiopulmonary Exercise Testing\n\nExclusion Criteria:\n\n* Unable to provide consent or perform oscillometry test",{"count":126,"type":20},"This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on Cardiopulmonary Exercise Testing in subjects who are experiencing shortness of breath.",[278,279,280,281],"Breathing, Mouth","Lung Function Decreased","Dyspnea","Shortness of Breath",{"date":283,"type":29},"2026-06-03",{"date":285,"type":29},"2024-10-29",{"date":287,"type":20},"2026-11-30",{"name":34,"class":35},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":43,"sex":16,"minAge":295,"maxAge":253,"enrollmentInfo":296,"targetDuration":4,"studyType":46,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":62},"100545300","stand-up-2-hpv-standing-orders-to-improve-hpv-vaccination-100545300","NCT06380114","Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination","Inclusion Criteria:\n\n* active patient in AHP practice\n\nExclusion Criteria:\n\n* patient belonging to a practice with \\>80% UTD baseline HPV vaccination rate for ages 13-17\n* patient belonging to a practice with \\\u003C20 11-12 year-olds eligible for an HPV dose","9 Years",{"count":297,"type":20},16000,[48],"Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, but have not been evaluated for HPV vaccine, which some parents consider controversial. Also, the ways in which organizational readiness for change (resources, motivation, staff attributes, leadership support and culture) moderate the effect of standing orders has not been studied. A physician's recommendation is correlated with HPV vaccine acceptance, and the investigators have developed a successful online, interactive, communication education program that will be adapted to train nurses and staff in addition to physicians. The investigators propose testing standing orders for HPV vaccine in an Accountable Care Organization (ACO) in Western New York, and assessing which provider and practice factors moderate the effect of standing orders. Advantages of this setting include a diverse group of rural, urban and suburban practices, and the ACO provides data infrastructure and analytics that allow practices to evaluate vaccination rates in real time.\n\nUsing a 2-arm cluster randomized trial (n=40 practices), the investigators will assess the effectiveness of standing orders (SO) + HPV communication education (intervention arm) relative to HPV communication education alone (control arm) on HPV vaccination for 9-17 year-olds.",[301],"Hpv","2026-05-26",{"date":304,"type":29},"2026-05-29",{"date":306,"type":29},"2024-11-04",{"date":308,"type":20},"2028-05",{"name":34,"class":35},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":46,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":62},"100454437","phase-1-imaging-of-lymphatic-vessels-in-people-with-rheumatoid-arthritis-ra-100454437","NCT05197530","Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)","Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green: Phase II Pilot","Inclusion Criteria:\n\nEarly RA\n\n* Ability to provide written informed consent\n* Subjects must be 18 years old or older\n* RA subjects must fulfill 2010 American College of Rheumatology (ACR) criteria with a DAS28-C-Reactive Protein (CRP) \\>3.5\n* Must have 1 year or less of disease\n* Must be MTX inadequate responder (DAS28-CRP \\>2.6 at 4 months of therapy) OR experience a flare on MTX (self-reported and score of \\>25 on the Outcome Measures in Rheumatology (OMERACT) Flare questionnaire AND are starting an anti-TNF therapy.\n* Must have active synovitis in one or both hands confirmed by ultrasound\n\nEstablished RA\n\n* Ability to provide written informed consent\n* Subjects must be 18 years of age or older\n* RA subjects must fulfill 2010 ACR criteria with a DAS-CRP \\>3.5\n* Must have at least 10 years of disease\n* Must have active synovitis in one or both hands confirmed by ultrasound\n* Must be on a stable dose of DMARD (MTX, leflunomide, azulfidine, hydroxychloroquine), Janus Kinase (JAK) inhibitor or biologic agent for 8 weeks\n\nExclusion Criteria: All PATIENTS\n\n* Active systemic disorders or inflammatory conditions other than RA, (i.e., chronic infections with hepatitis B, hepatitis C or HIV) that would confound the study results.\n* Known sensitivity to iodine because of residual iodide in Indocyanine Green\n* Pregnant women should not participate; pregnancy tests will not be performed\n* Inability to donate blood due to poor venous access",{"count":318,"type":20},40,[205],"Lymphatic transport was previously examined by these investigators using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities. They established reliable and reproducible methodologies in RA patients. The purpose of this phase 2 pilot is to study RA disease progression and effectiveness as well as the mechanism of action of clinical interventions using established NIR-ICG methodologies in previous studies.",[322],"Rheumatoid Arthritis",[324,325,326,327,328,322,329],"Near InfraRed","Lymphatic Transport","Imaging","Indocyanine Green","ICG","MSImager","2026-05-22",{"date":332,"type":29},"2026-05-27",{"date":334,"type":29},"2021-12-30",{"date":336,"type":20},"2026-06",{"name":34,"class":35},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":16,"minAge":345,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":46,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":62},"100637738","evaluation-of-a-patient-centered-decision-making-support-tool-for-older-adults-with-advanced-breast-cancer-and-their-care-partners-100637738","NCT07599618","Evaluation of a Patient-Centered Decision-Making Support Tool for Older Adults With Advanced Breast Cancer and Their Care Partners","PCDM","Inclusion Criteria:\n\nPatient Inclusion Criteria:\n\n1. A diagnosis of metastatic breast cancer\n2. Age 65 or older\n3. Currently receiving systemic treatment for metastatic breast cancer or considering a plan to initiate systemic treatment for metastatic breast cancer\n4. Able to speak and read English (because the Manta Cares platform is presently only offered in English only)\n5. Able to provide informed consent\n\nCare Partner Inclusion Criteria:\n\n1. Age 18 or older\n2. Able to speak and read English (because the Manta Cares platform is presently only offered in English only)\n3. Able to provide informed consent\n4. Verbal permission from patient to enroll their designated care partner\n\nExclusion Criteria:\n\nPatient Exclusion Criteria:\n\n1. Early-stage breast cancer\n2. Diagnosis of any other cancer besides metastatic breast cancer\n\nCare Partner Exclusion Criteria:\n\n1\\. Verbal permission from patient to enroll care partner not received.","65 Years",{"count":347,"type":20},150,[48],"The purpose of this study is to determine the feasibility for a patient centered decision-making support tool for older adults with metastatic breast cancer and their care partners.",[351],"Metastatic Breast Cancer","2026-05-21",{"date":302,"type":29},{"date":355,"type":20},"2026-08-01",{"date":357,"type":20},"2027-08-01",{"name":34,"class":35},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":43,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":62},"100640372","phase-resolved-functional-lung-mri-and-oscillometry-for-the-observation-of-healthy-lung-function-100640372","NCT07614685","Phase Resolved Functional Lung MRI and Oscillometry for the Observation of Healthy Lung Function","PROOF","Inclusion Criteria:\n\n* Age 18 years or older\n* Ability to provide consent\n* Willingness to perform MRI and breathing test\n* Must be able to speak and understand English\n\nExclusion Criteria:\n\n* Pregnant\n* Unable or willing to provide consent or perform the required maneuvers for testing.",{"count":231,"type":20},"This study will examine the relationship of airways resistance measured by oscillometry with ventilation defects measured by Phase Resolved Functional Lung (PREFUL) MRI in healthy human subjects.",[369,279,370,371],"Breathing","MRI Imaging","Healthy","2026-05-20",{"date":304,"type":29},{"date":28,"type":20},{"date":376,"type":20},"2028-01-01",{"name":34,"class":35},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":46,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100557827","primary-preventive-ventricular-tachycardia-ablation-in-high-risk-patients-who-receive-a-prophylactic-implantable-cardioverter-defibrillator-100557827","NCT06543173","Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator","Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator (PRIMARY PREVENT-VT TRIAL)","PREVENT-VT","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Willing and able to provide informed consent\n* Candidate for a primary prevention ICD\u002FCRT-D per ESC guidelines17\n* Ischemic cardiomyopathy (ICM) with left ventricular ejection fraction (LVEF) ≤ 35%\n* Willing and able to receive an ICD\n* Willing and able to undergo catheter-based VT ablation\n\nOne or more of the following:\n\n* MADIT-ICD Benefit Score \\>75\n* History of nonsustained ventricular tachycardia (NSVT)\n* Multiple premature ventricular complexes (PVCs ≥10%)\n\nExclusion Criteria:\n\n* Existing ICD or CRT-D\n* History of sustained VT or VF\n* Chronic renal failure requiring hemodialysis\n* Coronary revascularization within the past 3 months\n* ST-Elevation MI within the past 3 months\n* Participation in concurrent clinical trials without approval from the Coordination Center (observational registries are allowed with approval)\n* Currently pregnant or planning to become pregnant in the near future\n* Inability or unwillingness to adhere to the study protocol\n* Inability or unwillingness to provide informed consent for participation\n* Life expectancy \\\u003C 1 year",{"count":387,"type":20},62,[48],"This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.",[391],"Heart Failure","2026-05-14",{"date":394,"type":29},"2026-05-19",{"date":396,"type":29},"2026-01-22",{"date":398,"type":20},"2030-08-01",{"name":34,"class":35},5,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":46,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":62},"100615267","tele-savvy-for-latino-caregivers-100615267","NCT07290387","Tele-Savvy for Latino Caregivers","Inclusion Criteria:\n\n* Identify as Hispanic or Latino\n* Age 18 years or older\n* Spanish speaking and able to read and write in Spanish\n* Provide at least four hours per week of care to a community dwelling loved one with Alzheimer's disease or related dementias\n* Have access to an electronic device and internet\n* Willing to participate in study interviews and intervention sessions\n\nExclusion Criteria:\n\n* Physical or sensory conditions preventing use of a computer tablet or smartphone\n* Planning to move the care recipient to an institutional setting within six months",{"count":408,"type":20},64,[48],"Latino caregivers of individuals with Alzheimer's disease and related dementias experience high levels of stress burden and depressive symptoms and are underrepresented in caregiver intervention research. Tele Savvy is an evidence based caregiver education program that focuses on developing caregiver mastery skills. This study aims to culturally adapt the Tele Savvy intervention for Latino caregivers and evaluate its preliminary efficacy in a Stage 1b single arm clinical trial. The intervention is delivered remotely and includes weekly group sessions and asynchronous instructional videos. Primary outcomes focus on caregiver mastery with secondary outcomes including stress burden depressive symptoms and self efficacy.",[412,413,414],"Alzheimer Disease","Dementia","Caregiver Stress","2026-05-13",{"date":392,"type":29},{"date":418,"type":29},"2026-04-17",{"date":420,"type":20},"2027-05-31",{"name":34,"class":35},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":46,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":442,"locationsCount":62},"100626061","briter-eyez-moisture-vue-on-demand-disposable-moisture-chamber-100626061","NCT07430735","BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber","A Clinical Evaluation of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber in Subjects With Mild to Moderate Dry Eye Disease","Inclusion Criteria:\n\n* 18 years of age or older\n* Clinical Diagnosis of mild to moderate dry eye\n* Individual wears eyeglass spectacles\n\nExclusion Criteria:\n\n* Children under the age of 18 years of age\n* Women who are currently pregnant or nursing\n* Adults with decisional impairment\n* Prisoners\n* Individuals who have a known ocular or medical condition (other than DED) that impacts their ocular surface and could confound the results of the study.",{"count":430,"type":20},35,[48],"The purpose of this study is to evaluate the short-term effects (impact on tear film and dry eye symptoms) of the BriTer Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber (the device under investigation) in individuals with mild to moderate dry eye disease. Specifically, the study aims to determine whether wearing the device for two hours improves tear-film stability, tear volume, and tear osmolarity,",[434],"Dry Eye Disease (DED)",[436],"Dry Eye","2026-05-12",{"date":439,"type":29},"2026-05-15",{"date":236,"type":20},{"date":32,"type":20},{"name":34,"class":35},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":46,"phases":452,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":62},"100461211","phase-2-the-role-of-brain-dopamine-in-chronic-pain-100461211","NCT05285683","The Role of Brain Dopamine in Chronic Pain","The Role of Dopamine in the Central Neural Signature of Chronic Pain","Inclusion Criteria:\n\nThe following inclusion criteria must be met for all subjects to be considered eligible to participate:\n\n1. 18 years old or older\n2. Equal numbers of men and women, as well as racial and ethnic makeup representative of surrounding area\n3. Able to speak, read, and understand English\n4. In generally stable health\n5. Sign informed consent document\n\nThe following inclusion criteria must be met for chronic pain patients to be considered eligible to participate:\n\n1. Patients must report chronic pain for more than 1 year.\n2. The reported pain should be rated at ≥ 40\u002F100\n\nExclusion Criteria:\n\nGeneral exclusion criteria for all subjects include:\n\n1. Significant other medical disease, such as unstable diabetes mellitus, congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy\n2. History of traumatic brain injury (TBI)\n3. Current misuse\u002Fdependence on substance(s), including alcohol, at the time of study enrollment\n4. Major psychiatric disorder during the past 6 months\n5. Significantly abnormal laboratory values, which include, but are not limited to, the following:\n\n   1. White blood cell (WBC) \\\u003C 1.5 or \\>15.0 x 10\\^3\u002FμL\n   2. Hemoglobin (Hgb) \\\u003C 8 gm\u002FdL\n   3. Hematocrit (Hct) \\\u003C 24% or \\> 50%\n   4. Platelets (Plts) \\\u003C50 or \\> 1000 x10\\^3\n   5. Creatine \\> 2 mg\u002FdL\n   6. Glucose \\> 125 mg\u002FdL\n   7. Aspartate aminotransferase (AST) \\> 250 U\u002FL\n   8. Alanine Transaminase (ALT) \\> 250 U\u002FL\n   9. Bilirubin \\> 3 mg\u002FdL\n6. Intra-axial implants (e.g. - spinal cord stimulators or pumps)\n7. Inability to adequately perform the finger-span visual tracking task (training for rotating pain perception, see Brain Imaging Details).\n8. All MRI exclusionary criteria: any metallic implants, brain or skull abnormalities, tattoos on large body parts, pregnancy, and claustrophobia.\n9. In the judgement of the investigator, unable or unwilling to follow the protocol and instructions.\n10. Gambling addiction self-reported during screening process (ensure computer-based games do not cause psychological or emotional problems)\n11. Chronic pain patients with past history of allergic reactions to methylphenidate or levodopa\u002Fcarbidopa.\n\nFor healthy control subjects, current complaint(s) of pain, or a history of pain lasting \\>4 weeks in the last year, will be excluded from participating.\n\nIn addition, exclusion criteria for chronic pain subjects also includes:\n\n1. Pain that is associated with any systemic signs or symptoms (e.g. - fever, chills)\n2. Evidence of rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures, fibromyalgia, history of tumor(s) in the back.\n3. Involvement in litigation regarding their pain, or having a disability claim, or receiving workman's compensation, or seeking either because of their pain.\n4. Treated with methadone for opioid use disorder (i.e. - not just for pain)",{"count":451,"type":20},10,[453],"PHASE2","Chronic pain is associated with plasticity in the brain limbic system composed mainly of the amygdala, hippocampus, ventral striatum, and cingulate cortex (ACC) \u002Fmedial prefrontal cortex (mPFC). These brain areas, especially the ventral striatum, receive dopaminergic input from the ventral-tegmental area (VTA). Although there is a significant literature now showing that limbic brain tracks chronic pain intensity and predicts the risk of transition from sub-acute to chronic pain, the role of dopaminergic input to the limbic brain and the change thereof which occurs in chronic pain, is still not clear.\n\nGiven the role of dopamine in motivational control and the loss of motivation associated with chronic pain understanding how dopaminergic transmission is altered in the limbic brain of chronic pain patients is critical to the understanding of the pathophysiology of chronic pain. Therefore, the overall aim of this project is to use brain imaging to study how dopaminergic transmission through the oral administration of pro-dopaminergic medications carbidopa\u002Flevodopa (CD\u002FLD) and methylphenidate will modulate the brain signature of chronic pain. Chronic pain subjects will be scanned at baseline (no drug administration) and three times after treatment with the two drugs or placebo. The protocol will follow a randomized double-blind approach.",[456],"Chronic Pain",[458,459,460],"dopamine","loss of motivation","chronic back pain",{"date":439,"type":29},{"date":463,"type":29},"2024-01-31",{"date":465,"type":20},"2027-12-22",{"name":34,"class":35},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":16,"minAge":345,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":46,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":62},"100622932","exercise-and-cognitive-rehabilitation-interventions-for-older-cancer-survivors-100622932","NCT07390045","Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors","Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors: A Pilot Randomized Controlled Trial","ECO 2","Inclusion criteria:\n\n* Age ≥65 years (from date of consent, confirmed on the electronic medical record)\n* A diagnosis of any cancer\n* Have completed curative intent treatments\n\n  * Patients on endocrine therapies are allowed to enroll\n  * Patients with hematologic malignancies after autologous or allogeneic stem cell transplant are allowed to enroll if they have completed curative-intent treatment\n* Answered \"yes\" to the verbal question \"Do you have concerns about memory or other thinking abilities following your cancer treatment?\"\n* Able to speak English (interventions are available in English only)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3#\n* No medical contraindications to exercise#\n* Able to walk 4 meters#\n* Able to provide informed consent#\n\n  * Confirmed through eligibility confirmation with the patient's oncologist or their designee\n\nExclusion criteria:\n\n* Any physical, psychological, or social impairments that would interfere with a patient's ability to participate in the study as determined by the patient's oncologist or their designee\n* Unwilling to complete study procedures",{"count":318,"type":20},[48],"The objective of this study is to assess the preliminary effects of an integrated exercise and cognitive rehabilitation intervention (ECO), an exercise intervention (EXCAP), and a cognitive rehabilitation intervention (MAAT) as compared to usual care on objective cognition (Trail Making Test).",[479],"Cancer",[481,482,483,484,485],"geriatric oncology","cancer survivors","exercise","cognitive rehabilitation","cognition","2026-05-11",{"date":415,"type":29},{"date":489,"type":20},"2026-05-01",{"date":491,"type":20},"2028-03-31",{"name":34,"class":35},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":228,"minAge":17,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":46,"phases":502,"briefSummary":503,"conditions":504,"keywords":510,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":62},"100544518","tens-analgesia-during-outpatient-urethral-bulking-for-stress-urinary-incontinence-100544518","NCT06369922","TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","Transcutaneous Electrical Nerve Stimulation Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.","TENSUB","Inclusion Criteria:\n\n* • Women, Age ≥18 years\n\n  * Diagnosis of SUI\n  * Scheduled to undergo transurethral bulking in the office\n  * Able to read\u002Fwrite English\n\nExclusion Criteria:\n\n* • Cutaneous damage such as ulcers or broken skin on target treatment area\n\n  * Currently implanted cardiac pacemaker or defibrillator\n  * Pre-procedural use of opioids for pain management, less than 8 hours from last dose\n  * Participants with altered sensation below the umbilicus",{"count":255,"type":20},[48],"This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS.",[505,506,507,508,509],"Stress Incontinence Female","Urinary Incontinence","Urinary Incontinence,Stress","Pain","Pain Acute",[511,512,513],"TENS","pain","Transcutaneous Electrical Nerve Stimulation Analgesia",{"date":415,"type":29},{"date":516,"type":29},"2024-07-01",{"date":518,"type":20},"2027-06-01",{"name":34,"class":35},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":46,"phases":529,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":62},"100474338","digital-cbt-for-insomnia-and-depression-100474338","NCT05456607","Digital CBT for Insomnia and Depression","Optimizing Digital Behavioral Treatment for Co-occurring Insomnia and Depression","Inclusion Criteria:\n\n* English-speaking\n* U.S. Military Veterans\n* endorse depression (Patient Health Questionnaire-depression score \\> 10)\n* endorse insomnia (Insomnia Severity Index score \\> 10).\n\nExclusion Criteria are limited in accordance with real world effectiveness trials, but will include:\n\n* pregnancy\n* history of bipolar disorder\n* history of psychosis\n* current use of anti-psychotic medications or mood stabilizers (e.g., lithium)\n* current suicidal ideation with active intent",{"count":528,"type":20},1200,[48],"This study has two primary objectives, each of which addresses critical clinical and research gaps for individuals who have co-occurring insomnia and depression. The first objective is to address whether sequential treatment of insomnia and depression is superior to a single treatment for either depression or for insomnia, and if so, which treatment sequence is optimal. The second objective is to determine if there are heterogeneity of treatment effects; that is, variation in which interventions are best for which individuals, and if so, to develop and individualized intervention rule to better match individuals with the treatment that is most likely to lead to the best outcomes. A large randomized trial will be conducted to meet these objectives.",[532,77],"Depression",[534,535,536,537],"cognitive behavioral therapy","digital intervention","depression","insomnia","2026-05-05",{"date":486,"type":29},{"date":541,"type":29},"2023-05-01",{"date":543,"type":20},"2027-09-18",{"name":34,"class":35},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":16,"minAge":553,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":46,"phases":556,"briefSummary":557,"conditions":558,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":400},"100547605","chronic-kidney-disease-education-ckd-edu-100547605","NCT06410144","Chronic Kidney Disease-Education (CKD-EDU)","Improving Kidney Therapy Decision-Making for Older People With Advanced Chronic Kidney Disease (CKD)","CKD-EDU","Inclusion Criteria:\n\n* Age ≥ 75 years old\n* Has advanced kidney disease with kidney function less than 30%\n* Speaks English\n* Has not yet made a dialysis decision\n\nExclusion Criteria:\n\n* Has already decided on dialysis or active medical care without dialysis.\n* Has already been seen by a Palliative Care (PC) clinician for kidney-related issues or is enrolled in hospice\n* Currently on dialysis\n* Unable to provide informed consent or complete verbally administered surveys due to health, sensory, or cognitive impairment.","75 Years",{"count":555,"type":20},326,[48],"The investigators are conducting a study to see which program better helps older patients with kidney disease choose their treatment. Investigators are also investigating if either program can reduce the number of hospital or emergency room visits in the first 6 months of the study, as well as potentially improve end-of-life care for older adults.\n\nHalf of the participants will receive Program A, while the other half will receive Program B. Investigators will compare the two groups to see which participants feel better prepared about their kidney therapy decisions, experience improved end-of-life care, and have fewer emergency room visits and hospital admissions.\n\nParticipants in Program A will receive information from the National Kidney Foundation and meet with a kidney therapy educator. Participants in Program B will get information about kidney disease treatment and meet with a decision-support specialist who's an expert in decision-making.",[559],"Chronic Kidney Diseases","2026-04-29",{"date":538,"type":29},{"date":563,"type":29},"2025-02-27",{"date":565,"type":20},"2028-12-31",{"name":34,"class":35},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":16,"minAge":574,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":46,"phases":578,"briefSummary":579,"conditions":580,"keywords":584,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":4},"100636479","increasing-lung-cancer-screening-among-emergency-department-patients---lcs-r01-100636479","NCT07566221","Increasing Lung Cancer Screening Among Emergency Department Patients - LCS R01","Increasing Lung Cancer Screening Uptake Among Emergency Department Patients - LCS R01","Inclusion Criteria:\n\n* Age 50 - 80\n* ≥ 20 pack-year smoking history\n* current smoker or quit within 15 years\n* English\u002FSpanish speaking\n* Registered in the Emergency Department as a patient\n\nExclusion Criteria:\n\n* Non-English\u002FSpanish\n* Inability to provide consent (e.g. high clinical acuity, cognitive deficit)\n* Lack of text-capable mobile phone and\u002For inability to use text function","50 Years","80 Years",{"count":577,"type":20},1036,[48],"This randomized clinical trial evaluates the effectiveness of text messaging and facilitated referral strategies to increase lung cancer screening uptake among emergency department patients who meet lung cancer screening eligibility criteria.",[581,582,583],"Smoking History","Current Smoker","Lung Cancer Screening",[583,585,586],"Emergency Department","Smoking","2026-04-28",{"date":538,"type":29},{"date":590,"type":20},"2027-03-01",{"date":592,"type":20},"2031-12-01",{"name":34,"class":35},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":43,"sex":16,"minAge":600,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":62},"100636727","auditory-eeg-and-behavioral-assessments-in-individuals-with-rett-syndrome-100636727","NCT07569445","Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome","Rett Syndrome Participants:\n\nInclusion Criteria:\n\n* Have a clinical diagnosis of classic Rett syndrome\n* Have a pathogenic MECP2 genetic variant confirmed via genetic testing\n* Are past the clinical regression stage\n* Are within the eligible age range for the study (2 years or older)\n* Are able to tolerate the noninvasive EEG recording\n* Parent or caregiver is willing and able to provide parental permission and complete questionnaires and interviews\n\nExclusion Criteria:\n\n* Experiences hearing impairment or hearing loss\n* Presence of medical conditions that would prevent safe participation in EEG recording\n* Inability to tolerate EEG procedures\n* Any condition that in the opinion of the investigator would interfere with study participation or data quality\n\nControls\n\nInclusion Criteria:\n\n* Neurologically healthy individuals ages 2 years or older\n* Are able to tolerate the noninvasive EEG recording\n\nExclusion Criteria:\n\n* Experiences hearing impairment or hearing loss\n* Medical history of genetic, neurological, or psychiatric disorders\n* History of special education services\n* Inability to tolerate EEG procedures\n* Any condition that in the opinion of the investigator would interfere with study participation or data quality","2 Years",{"count":203,"type":20},"This observational research study is designed to learn more about how the brain processes sound in individuals with Rett syndrome. Participants will complete a noninvasive electroencephalogram (EEG) recording while listening to simple sounds through headphones. In addition, parents or caregivers will complete questionnaires and an interview about the participant's symptoms, communication abilities, daily functioning and overall health. The information collected from this study may help researchers better understand brain activity patterns and clinical features associated with Rett syndrome and support future research efforts.",[604],"Rett Syndrome",[606,607,608,609],"Electroencephalography","EEG","Brain activity","Biomarkers",{"date":611,"type":29},"2026-05-06",{"date":613,"type":29},"2025-07-31",{"date":615,"type":20},"2027-08",{"name":34,"class":35},""]